Heron Therapeutics Announces Poster Presentations of Data from Phase 2 Clinical Program for HTX-011 at PAINWeek® 2016
08/29/2016
|
Presentation details are as follows:
Poster Title: | Local Administration of HTX-011, a Long-Acting Biochronomer-Based Bupivacaine/Meloxicam Combination, in Hernia Repair: Initial Results | |||||||||
Author/Presenter: |
Peter J. Winkle, MD, FACP, CPI, FACG, Anaheim Regional Medical Center, Anaheim Clinical Research |
|||||||||
Poster Number: | 144 | |||||||||
Date/Time: | Thursday, September 8, 2016 from 6:30 PM – 8:30 PM PT | |||||||||
Location: | Level 3, Gracia 7 |
Poster Title: | Local Administration of HTX-011, a Long-Acting Biochronomer-Based Bupivacaine/Meloxicam Combination, in Hernia Repair Provides Similar Initial Results Whether Injected, Instilled, or Both | |||||||||
Author/Presenter: | Harold S. Minkowitz, MD, Diplomat American Board of Anesthesiology, Department of Anesthesiology, Memorial Hermann Memorial City Medical Center | |||||||||
Poster Number: | 90 | |||||||||
Date/Time: | Thursday, September 8, 2016 from 6:30 PM – 8:30 PM PT | |||||||||
Location: | Level 3, Gracia 7 | |||||||||
About
Forward-Looking Statements
This news release contains "forward-looking statements" as defined by
the Private Securities Litigation Reform Act of 1995. Heron cautions
readers that forward-looking statements are based on management’s
expectations and assumptions as of the date of this news release and are
subject to certain risks and uncertainties that could cause actual
results to differ materially, including, but not limited to, those
associated with: whether the Phase 2 study results are indicative of the
results in future studies related to HTX-011, the sufficiency of the
Phase 2 data to allow the commencement of Phase 3 registration studies
for HTX-011, the potential market opportunity for HTX-011, and other
risks and uncertainties identified in the Company's filings with the
View source version on businesswire.com: http://www.businesswire.com/news/home/20160829005158/en/
Source:
Investor Relations and Media Contact:
Heron Therapeutics,
Inc.
Jennifer Capuzelo, 858-703-6063
Associate Director,
Investor Relations
jcapuzelo@herontx.com